BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Medigus Announces $8 Million Private Placement to OrbiMed


3/14/2013 7:11:45 AM

OMER, Israel, March 13, 2013 /PRNewswire/ -- Medigus Ltd. (MDGS.TA), a leading medical device company dedicated to the development of innovative endoscopic procedures and technologies, announced today the closing of a private equity placement of $8 million to OrbiMed Israel Partners Limited Partnership, an affiliate of OrbiMed Advisors LLC, a leading healthcare investment firm. OrbiMed has been issued 39.9 million ordinary shares of Medigus, which account for 30.7% of Medigus' shares.

(Logo: http://photos.prnewswire.com/prnh/20130313/601331

Upon the closing of the investment, Dr. Nissim Darvish, Senior Managing Director at OrbiMed Israel, was appointed chairman of the board of directors of Medigus. In addition, Anat Naschitz and Erez Chimovits, both Managing Directors at OrbiMed Israel, and Chris Rowland joined the board.

"We are proud to welcome OrbiMed as our largest shareholder, and are grateful for their confidence in our company and for their vision," said Medigus' CEO Dr. Elazar Sonnenschein. "At the critical juncture where we stand, namely the transition from R&D operations to the commercial marketing of our systems in several markets worldwide, the great expertise and financial liquidity offered by OrbiMed will help the company maximize the commercial potential of our SRS™ innovative endoscopy system for the treatment of Gastroesophageal Reflux Disease (GERD) in the US, Europe and East Asia."

"We are excited about Medigus and look forward to working together towards commercial success," said Dr.Nissim Darvish and Ms. Naschitz. "Medigus is well positioned to become a leader in minimally invasive surgery, due to its innovative technology, high quality standards and talented personnel. The company offers an appealing combination of market-ready products and a broad pipeline."

About Medigus Ltd.

Medigus (MDGS.TA) is a medical device company headquartered in Omer, Israel, specializing in developing innovative endoscopic procedures and devices. Medigus is a pioneer developer of a unique proprietary endoscopic device for the treatment of GERD, one of the most common chronic diseases in the western world. In addition, Medigus has developed the world's smallest camera for endoscopic use as well as for other medical and industrial applications.

Based on its proprietary technologies, Medigus designs and manufactures endoscopy systems for partner companies, including major players in the medical device industry. Medigus has an advanced technology platform that includes all necessary elements for performing a wide range of endoscopic procedures. The platform includes multiple rigid, semi-flexible and flexible video endoscopes, as well as respective endoscopy suites.

About OrbiMed Advisors LLC

OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with approximately $6 billion in assets under management. OrbiMed invests across the spectrum of healthcare companies worldwide, from venture capital start-ups to large multinational companies. OrbiMed manages a series of private equity funds, public equity funds, royalty funds and other investment vehicles.

Contact:

Miri Segal-Scharia

Hayden/ MS-IR LLC

Tel: +1-917-607-8654

msegal@ms-ir.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES